Phio Pharmaceuticals

About:

Phio Pharmaceuticals is a biotechnology company specializing in the application of RNAi therapies in immuno-oncology.

Website: https://phiopharma.com

Twitter/X: phio_pharma

Top Investors: OPKO Health, Lincoln Park Capital Fund, TRITON FUNDS LLC

Description:

Phio Pharmaceuticals is a biotechnology company specializing in the application of RNAi therapies in immuno-oncology. Its proprietary INTASYL technology is a platform for self-delivering RNAi immuno-oncology therapies. It is a patented platform from which unique patented compounds are created to silence genes that tumors use to evade the immune system.

Total Funding Amount:

$116M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Marlborough, Massachusetts, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)phiopharma.com

Founders:

Craig Mello, Michael Czech

Number of Employees:

11-50

Last Funding Date:

2024-07-12

IPO Status:

Public

Industries:

© 2025 bioDAO.ai